Dr. Rugo on the Future of Angiogenesis in Breast Cancer

Hope S. Rugo, MD
Published: Friday, Sep 09, 2011

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, explains that the future of angiogenesis inhibitors is an extremely complicated area.

Rugo expresses that the first step was to establish how important angiogenesis is in malignant progression, invasion, metastasis, and survival of metastatic disease. It is clear that angiogensis does play a role in tumor progression but that role has not yet been fully defined.

The process of angiogenesis has many functions both in tumors and normal cell function and this makes it extremely difficult to work with. In the future she believes combination therapies will need to be used in more effective and smarter ways in order to increase the efficacy of anti-angiogenesis treatments.
Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, explains that the future of angiogenesis inhibitors is an extremely complicated area.

Rugo expresses that the first step was to establish how important angiogenesis is in malignant progression, invasion, metastasis, and survival of metastatic disease. It is clear that angiogensis does play a role in tumor progression but that role has not yet been fully defined.

The process of angiogenesis has many functions both in tumors and normal cell function and this makes it extremely difficult to work with. In the future she believes combination therapies will need to be used in more effective and smarter ways in order to increase the efficacy of anti-angiogenesis treatments.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x